logo
Медицинский вестник
Северного Кавказа
Научно-практический журнал
Зарегистрирован в Федеральной службе
по надзору за соблюдением законодательства
в сфере массовых коммуникаций
и охране культурного наследия
ПИ №ФС77-26521 от 7 декабря 2006 года
ISSN 2073-8137
rus
русский
eng
english

Поиск по сайту




Адрес редакции
355017, Ставрополь, улица Мира, 310.

Телефоны
(8652) 35-25-11, 35-32-29.

E-mail
medvestnik@stgmu.ru

Рейтинг@Mail.ru

Управление лечением на основе приверженности. Консенсусный документ – клинические рекомендации. Англоязычная версия

[Клинические рекомендации]
Николаев Николай Анатольевич; Мартынов Анатолий Иванович; Скирденко Юлия Петровна; Анисимов В. Н.; Васильева И. А.; Виноградов О. И.; Виноградов О. И.; Лазебник Л. Б.; Поддубная И. В.;

Согласительный документ «Управление лечением на основе приверженности» разработан на основе клинических рекомендаций Российского научного медицинского общества терапевтов, одобренных XIV Национальным конгрессом врачей (Москва, 20 ноября 2019 г.). Документ предназначен в первую очередь для оценки приверженности лекарственной терапии, модификации образа жизни и медицинского сопровождения пациентов, нуждающихся в длительном или постоянном лечении. Приверженность лечению рассматривается авторами документа как соответствие поведения пациента полученным от врача рекомендациям относительно медикаментозного лечения, диеты и других мер по изменению образа жизни. Недостаточная приверженность лечению является глобальной проблемой. Оценка приверженности как основа принятия медицинских решений является важным элементом повышения качества системы здравоохранения. Прогнозы результатов лечения не могут считаться эффективными, если индивидуальные уровни приверженности не используются для обоснования планирования и оценки проекта. В медицинской практике предпочтительна количественная оценка приверженности, подходящая для пациентов с различными заболеваниями и с возможностью автоматизированного ввода и обработки данных. Разделы, посвященные медицинским вмешательствам, основанным на оценке приверженности лечению, должны быть отражены в национальных клинических рекомендациях. На этих ключевых положениях базируются настоящие совместные рекомендации.

Скачать

Список литературы:
1. Geest S., Sabate E. Adherence to long-term therapies:evidence for action.Eur. J. Cardiovasc. Nurs.2003;2(4):323. https://doi.org/10.1016/S1474-5151(03)00091-4
2. Alekseev V. N., Malevannaya O. A., El Haj N. S. The reasons of low adherence in primary open-angle glaucoma patients treatment. Ophthalmological journal. 2010;3(4):37-39. [cited 05.01.2020]. Available at: https://elibrary.ru/download/elibrary_15555091_58697945.pdf.
3. Moisseyev S. V. How to improve compliance to dual antithrombotic treatment after acute coronary syndrome? Clin. Pharmacol. Ther. 2011;20(4):34-40. [cited 05.01.2020]. Available at: https://elibrary.ru/download/elibrary_22622404_71748330.pdf.
4. Nikolaev N. A., Martynov A. I., Bojcov S. A., Drapkina O. M., Sychev D. A. [et al.] The first Russian consensus on quantitative assessment of treatment outcome. Medical News of North Caucasus. 2019;2(14):283-301. https://doi.org/10.14300/mnnc.2019.14072
5. Corrao G., Parodi A., Nicotra F., Zambon A., Merlino L. [et al.] Better compliance to antihypertensive medications reduces cardiovascular risk. J. Hypertens. 2011;29:610-618. https://doi.org/10.1097/HJH.0b013e328342ca97
6. Tiffe T., Wagner M., Rucker V., Morbach C., Gelbrich G. [et al.] Control of cardiovascular risk factors and its determinants in the general population-findings from the STAAB cohort study. BMC Cardiovasc Disord. 2017;17:276. https://doi.org/10.1186/s12872-017-0708-x
7. World Health Organization. Adherence to long-term therapies: evidence for action. WHO Library Cataloguingin-Publication Data, Geneva, WHO 2003;211. [cited 05.01.2020]. Available at: https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf.
8. Berra E., Azizi M., Capron A., Hoieggen A., Rabbia F. [et al.] Evaluation of adherence should become an integral part of assessment of patients with apparently treatmentresistant hypertension. Hypertension. 2016;68:297-306. https://doi.org/10.1161/HYPERTENSIONAHA.116.07464
9. Nlkolaev N. Patient-oriented antihypertensive therapy: clinical guidelines for the practitioner. The Doctor. 2016;4:82-85. [cited 05.01.2020]. Available at: https://elibrary.ru/item.asp?id=25934065.
10. Skirdenko Y. P., Nikolaev N. A. Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation. Russian Journal of Cardiology. 2019;(2):64-69. https://doi.org/10.15829/1560-4071-2019-2-64-69
11. Skirdenko Ju. P., Nikolaev N. A. Quantitative assessment of adherence to treatment in patients with atrial fibrillation in real clinical practice. Therapeutic Archive. 2018;1:17-21. https://doi.org/10.17116/terarkh201890117-21
12. Mancia G., Rea F., Cuspidi C., Grassi G., Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J. Hypertens. 2017;35:225-233. https://doi.org/10.1097/HJH.0000000000001181
13. Nikolaev N. A. Dokazatel’naya gipertenziologiya: kolichestvennaya ocenka rezul’tata antigipertenzivnoj terapii. M.: Izdatel’skij dom «Akademiya estestvoznaniya». 2008:92. Available at: https://elibrary.ru/item.asp?id=19544653
14. Nikolaev N. A. Dokazatel’naya gipertenziologiya: pacientoorientirovannaya antigipertenzivnaya terapiya. M.: Izdatel’skij dom Akademii estestvoznaniya. 2015:178. Available at: https://elibrary.ru/item.asp?id=25268177.
15. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39:3021-3104. https://doi.org/10.1093/eurheartj/ehy339
16. Souza A. C., Borges J. W., Moreira T. M. Quality of life and treatment adherence in hypertensive patients: systematic review with meta-analysis. Revista de Saúde Pública. 2016;50:71. https://doi.org/10.1590/s1518-8787.2016050006415
17. Marin M., Barochiner J., Rodriguez P., Renna N., Castellaro C. [et al.] Blood pressure control and cardiovascular risk profile in hypertensive patients under spe-cialist care in Argentina: results from the CHARTER study. J. Clin. Hypertens. 2019;21(10):1456-1462. https://doi.org/10.1111/jch.13684
18. Nikolayev N. A., Skirdenko Yu. P. Russian generic questionnaire for evaluation of compliance to drug therapy. Clin. Pharmacol. Ther. 2018;27(1):74-78. [cited 05.01.2020]. Available at: https://clinpharmjournal.ru/files/articles/rossijskij-universalnyj-oprosnikkolichestvennoj-otsenki-priverzhennosti-k-lecheniyukop-25.pdf.
19. Skirdenko Yu.P., Nikolaev N. A. Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation. Russian Journal of Cardiology. 2019;24(2):64-69. https://doi.org/10.15829/1560-4071-2019-2-64-69
20. Nikolaev N. A., Skirdenko Yu. P., Livzan M. A., Zamakhina O. V. Patient-centered technologies for risk assessment and prognosis of therapy efficacy in cardiology patients: a monograph. Omsk State Medical University. М.: Publishing House of the Academy of Natural Sciences. 2019:232. https://doi.org/10.17513/np.377
21. Ickovics J. R., Meisler A. W. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J. Clin. Epidemiol. 1997;50(4):385-91. https://doi.org/10.1016/S0895-4356(97)00041-3
22. Kastrissios H., Suarez J. R., Hammer S., Katzenstein D., Blaschke T. F. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS. 1998;12(17):2305-2311. https://doi.org/10.1097/00002030-199817000-00012
23. Rotar O. P., Tolkunova K. M., Solntsev V. N., Erina A. M., Boyarinova M. A. [et al.] May Measurement Month 2019: adherence to treatment and hypertension control in Russia. Russian Journal of Cardiology. 2020; 25(3):3745. https://doi.org/10.15829/1560-4071-2020-3-3745
24. Konradi A. O. Znachenie priverzhennosti k terapii v lechenii kardiologicheskih zabolevanij. Spravochnik poliklinicheskogo vracha. 2007;6:8-11.
25. Lomakin N. V., Buryachkovskaya L. I., Senichkina A. A., Sumarokov A. B., Docenko U. V. [et al.] Use of combination pills with acetylsalicylic acid and clopidogrel in coronary artery disease. Efficacy and assessment of adherence to treatment: Kobra Study. Consilium Medicum. 2021;23(1):61-69. https://doi.org/10.26442/20751753.2021.1.200780
26. Corrao G., Zambon A., Parodi A., Poluzzi E., Baldi I. [et al.] Discontinuation of and changes in drug therapy for hypertension amongnewly-treated patients: a populationbased study in Italy. J. Hypertens. 2008;26:819-824. https://doi.org/10.1097/HJH.0b013e3282f4edd7
27. Gale N. K., Greenfield S., Gill P., Gutridge K., Marshall T. Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Fam. Pract. 2011;12:59 [cited 05.01.2020]. Available at: https://bmcfampract.biomedcentral.com/articles/10.1186/1471-2296-12-59
28. Krousel-Wood M., Joyce C., Holt E., Muntner P., Webber L. S. [et al.] Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58:804-810. https://doi.org/10.1161/HYPERTENSIONAHA.111.176859
29. Andreev K. A., Plinder M. A., Sidorov G. G., Skirdenko Yu. P., Nikolaev N. A. Osnovnye trendy priverzhennosti k lecheniyu u kardiologicheskih bol’nyh. Sovremennye problemy nauki i obrazovaniya. 2018;3:36-36. [cited 05.01.2020]. Available at: https://rae.ru/pdf/bookspno_volume_3.pdf.
30. Skirdenko Ju. P., Zherebilov V. V., Nikolaev N. A. Predictors of adherence to treatment in patients with atrial fibrillation. International Journal of Applied and Fundamental Research. 2016;5. [cited 05.01.2020]. Available at: www.science-sd.com/467-25081
31. Ionov M. V., Zvartau N. E., Dubinina E. A., KhromovBorisov N. N., Tregubenko I. A. [et al.] Hypertension specific patient-reported outcome measure. Part III: validation, responsiveness and reliability assessment. Russian Journal of Cardiology. 2020;25(3):3438. https://doi.org/10.15829/1560-4071-2019-3438
32. Anghel L. A., Farcas A. M., Oprean R. N. An overview of the common methods used to measure treatment adherence. Med. Pharm. Rep. 2019;92(2):117-122. https://doi.org/10.15386/mpr-1201
33. Lukina Yu. V., Kutishenko N. P., Martsevich S. Yu., Drapkina O. M. Questionnaires and scores for assessing medication adherence – advantages and disadvantages of the diagnostic method in research and actual clinical practice. Cardiovascular Therapy and Prevention. 2020;19(3):2562. https://doi.org/10.15829/1728-8800-2020-2562
34. Bakris G. L., Lindholm L. H., Black H. R., Krum H., Linas S. [et al.] Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-830. https://doi.org/10.1161/HYPERTENSIONAHA.110.156976
35. Laurent S., Schlaich M., Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380:591-600. https://doi.org/10.1016/S0140-6736(12)60825-3
36. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117. https://doi.org/10.1136/bmj.39553.670231.25
37. Burnier M. Managing’ resistance’: is adherence a target for treatment? Curr. Opin. Nephrol. Hypertens. 2014;23:439-443. https://doi.org/10.1097/MNH.0000000000000045
38. Zherebilov V. V., Skirdenko Yu. P., Nikolaev N. A. Gendernye osobennosti priverzhennosti k lecheniyu u bol’nyh stabil’noj stenokardiej. International journal of experimental education. 2016;4(3):509-510. [cited 05.01.2020]. Available at: https://www.expeducation.ru/pdf/2016/4-3/9868.pdf.
39. Zhilenko O. M., Kukengemer V. S., Nejfeld M. S., Skirdenko Yu. P. Priverzhennost’ k lecheniyu u bol’nyh hronicheskoj serdechnoj nedostatochnost’yu. Nauchnoe obozrenie. Medicinskie nauki. 2017;5:37-40. [cited 07.06.2019]. Available at: https://science-medicine.ru/ru/article/view?id=1033.
40. Lukina Yu. V., Martsevich S. Yu., Kutishenko N. P. The Moriscos-Green scale: the pros and cons of universal test, correction of mistakes. Rational Pharmacotherapy in Cardiology. 2016;12(1):63-65. https://doi.org/10.20996/1819-6446-2016-12-1-63-65
41. Nikolaev N. A., Martynov A. I., Skirdenko Yu. P., Anisimov V. N., Vasileva I. A. [et al.] Treatment management based on adherence: patient recommendation algorithms. Cross-disciplinary guidelines. Medical News of North Caucasus. 2020;15(4):461-468. https://doi.org/10.14300/mnnc.2020.15109
42. Nikolayev N. A., Skirdenko Y. P., Zherebilov V. V. Quantitative assessment of adherence to treatment in clinical medicine: protocol, procedure, interpretation. Kachestvennaya klinicheskaya praktika. 2016;(1):50-59. [cited 05.01.2020]. Available at: https://elibrary.ru/item.asp?id=26375081
43. Efremova E. V., Menzorov M. V., Sabitov I. A. Treatment compliance in patients with chronic heart failure and comorbidities. Klin. med. 2015;93(9):20-24. [cited 05.01.2020]. Available at: https://cyberleninka.ru/article/n/priverzhennost-lecheniyu-bolnyh-s-hronicheskoyserdechnoy-nedostatochnostyu-v-usloviyah-komorbidnosti
44. Ho P. M., Bryson C. L., Rumsfeld J. S. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35. https://doi.org/10.1161/CIRCULATIONAHA.108.768986
45. Hwang S. L., Liao W. C., Huang T. Y. Predictors of quality of life in patients with heart failure. Jpn. J. Nurs Sci. 2014;11(4):290-98.
46. Levine D. A., Morgenstern L. B., Langa K. M., Piette J. D., Mary A. M. [et al.] Recent trends in cost-related medication nonadherence among stroke survivors in the United States. Ann. Neurol. 2013;73(2):180-8. https://doi.org/10.1002/ana.23823
47. Fofanova T. V., Ageev F. T., Smirnova M. D., Svirida O. N., Kuzmina A. E. [et al.] National questionnaire of treatment compliance: testing and application in outpatient practice. System Hypertension. 2014;02:13-16. Available at: https://con-med.ru/magazines/hypertension/hypertension-02-2014/otechestvennyy_oprosnik_priverzhennosti_terapii_aprobatsiya_i_primenenie_v_ambulatornoy_praktike.
48. Arabidze G. G., Belousov Yu. B., Karpov Yu. A. Arterial’naya gipertoniya. Spravochnoe rukovodstvo po diagnostike i lecheniyu. M.: Remedium; 1999:225
49. Zhuravskaya N. Yu. Izuchenie priverzhennosti lekarstvennoj terapii bol’nyh serdechno-sosudistymi zabolevaniyami, perenesshih mozgovoj insul’t, dissertaciya na soiskanie uchenoj stepeni kand. med. nauk. Gosudarstvennyj nauchno-Issledovatel’skij centr profilakticheskoj mediciny. M.; 2015.
50. Aliotta S. L., Vlasnik Jon J., DeLor Bonnie. Enhancing Adherence to Long-Term Medical Therapy: A New Approach to Assessing and Treating Patients. Advances in Therapy. 2004;21(4):214-231. https://doi.org/10.1007/BF02850154
51. Chowdhury R., Khan H., Heydon E., Shroufi A. [et al.] Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur. Heart J. 2013;34(38):2940-2948. https://doi.org/10.1093/eurheartj/eht295
52. Driving Therapy Adherence for Improved Health Outcomes. A Manifesto for the European Elections 2019. [cited 05.01.2020]. Available at: http://www.seniorinternationalhealthassociation.org/wp-content/uploads/2015/05/SIHA_Manifesto_Booklet_Online-version_without-sign_spread.pdf
53. World Health Organization. Secondary prevention of non-communicable disease in low and middle-income countries through community-based and health service interventions. 2002. [cited 05.01.2020]. Available at: www.who.int/chp/knowledge/publications/adherence_full_report.pdf
54. McDonnell P. J., Jacobs M. R. Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. 2002;36(9):1331-6. https://doi.org/10.1345/aph.1A333
55. Misdrahi D., Llorca P. M., Lançon C., Bayle F. J. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale. 2001;28(3):266-72. [cited 05.01.2020]. Available at: https://europepmc.org/article/med/12091789
56. Osterberg L., Blaschke T. Adherence to medication. N. Engl. J. Med. 2005;353(5):487-97. https://doi.org/10.1056/nejm200511033531819
57. Rodgers P. T., Ruffin D. M. Medication nonadherence: Part II--A pilot study in patients with congestive heart failure. Manag. Care Interface. 1998;11(9):67-9. [cited 05.01.2020]. Available at: https://europepmc.org/article/med/10187590.
58. Schiff G. D., Fung S., Speroff T., McNutt R. A. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am. J. Med. 2003;114(8):625-630. https://doi.org/10.1016/S0002-9343(03)00132-3
59. Senst B. L., Achusim L. E., Genest R. P., Cosentino L. A., Ford C. C. [et al.] Practical approach to determining costs and frequency of adverse drug events in a health care network. Am. J. Health Syst. Pharm. 2001;58(12):1126-32. https://doi.org/10.1093/ajhp/58.12.1126
60. Nikolaev N. A., Skirdenko Yu. P. Assessment of individual risk of food interactions against the background of warfarin. Terapevticheskiy arkhiv. 2021;2;187-192. https://doi.org/10.26442/00403660.2021.02.200611
61. Stevens V. J., Obarzanek E., Cook N. R., Lee I. M., Appel L. J. [et al.] Trials for the Hypertension Prevention Research G. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann. Intern. Med. 2001;134:1-11. [cited 05.01.2020]. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.868.1085&rep=rep1&type=pdf
62. Whelton P. K., Appel L. J., Espeland M. A., Applegate W. B., Ettinger W. H. [et al.] Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839-846. https://doi.org/10.1001/jama.279.11.839
63. Puchin’yan N. F., Dovgalevskiy Ya. P., Dolotovskaya P. V., Furman N. V. The adherence to recommended therapy in patients after acute coronary syndrome, and risk of cardiovascular complications within a year after hospital admission. Rational Pharmacother. Card. 2011;7(5):567-573. https://doi.org/10.20996/1819-6446-2011-7-5-57-61
64. Claxton A. J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 2001;23(8):1296–310. https://doi.org/10.1016/S0149-2918(01)80109-0
65. Waeber B., Leonetti G., Kolloch R., McInnes G. T. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J. Hypertens. 1999;17(7):1041–1045. [cited 05.01.2020]. Available at: https://journals.lww.com/jhypertension/Abstract/1999/17070/Compliance_with_aspirin_or_placebo_in_the.22.aspx.
66. Mazzaglia G., Ambrosioni E., Alacqua M., Filippi A., Sessa E. [et al.] Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-605. https://doi.org/10.1161/CIRCULATIONAHA.108.830299
67. Naderi S. H., Bestwick J. P., Wald D. S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 2012;125:882-887. https://doi.org/10.1016/j.amjmed.2011.12.013
68. Benson J., Britten N. Patients’ views about taking antihypertensive drugs: questionnaire study. BMJ. 2003;326(7402):1314-1315. https://doi.org/10.1136/bmj.326.7402.1314
69. Gupta P., Patel P., Strauch B., Lai F. Y., Akbarov A. [et al.] Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042-1048. https://doi.org/10.1161/HYPERTENSIONAHA.117.09631
70. Jung O., Gechter J. L., Wunder C., Paulke A., Bartel C. [et al.] Resistant hypertension? Assessment of adherence by toxicological urine analysis. J. Hypertens. 2013;31:766-774. https://doi.org/10.1097/HJH.0b013e32835e2286
71. Tomaszewski M., White C., Patel P., Masca N., Damani R. [et al.] High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatographytandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861. https://doi.org/10.1136/heartjnl-2013-305063
72. Hohlov A. L., Lisenkova L. A., Rakov A. A. Analiz faktorov, opredelyayushchih priverzhennost’ k antigipertenzivnoj terapii. Kachestvennaya klinicheskaya praktika. 2003;(4):59-66. [cited 05.01.2020]. Available at: https://www.clinvest.ru/jour/article/view/301
73. Fedorin M. M., Gorbenko A. V., Andreev K. A., Okhotnikova P. I., Demko I. V. [et al.] Medical background and potential adherence to treatment – solid cross-sectional surprises. The Russian Journal of Preventive Medicine. 2020; 23(6):15-21. https://doi.org/10.17116/profmed20202306115
74. Birtwhistle R. V., Godwin M. S., Delva M. D., Casson R. I. [et al.] Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ. 2004;328(7433):204. https://doi.org/10.1136/bmj.37967.374063.EE
75. Pharmaceutical Group of the European Union (PGEU), «Targeting Adherence», May 2008. [cited 05.01.2020]. Available at: https://www.pgeu.eu/en/policy/5-adherence.html
76. Fesenko E. V., Konovalov Ya. S., Aksenov D. V., Perelygin K. V. Sovremennye problemy obespecheniya priverzhennosti pacientov pozhilogo vozrasta s serdechnososudistoj patologiej k farmakoterapii. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya Medicina. Farmaciya. 2011;22(16/1):95-99. [cited 05.01.2020]. Available at: https://elibrary.ru/download/elibrary_17439814_84905831.pdf.
77. Coleman C. I., Limone B., Sobieraj D. M., Lee S., Lee S. [et al.] Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 2012;18(7):527-39. https://doi.org/10.18553/jmcp.2012.18.7.527
78. Schedlbauer A., Davies P., Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane database Syst. Rev. 2010;3:CD004371. https://doi.org/10.1002/14651858.CD004371.pub2
79. Alekseyeva T. S., Ogarkov M. Yu., Skripchenko A. E., Yankin M. Yu. Factors influencing compliance with lifestyle modification in an organized population. Systemic Hypertension. 2013;10(2):19-22. [cited 05.01.2020]. Available at: https://con-med.ru/magazines/hypertension/hypertension-02-2013/faktory_vliyayushchie_na_priverzhennost_k_modifikatsii_obraza_zhizni_v_organizovannoy_populyatsii/.
80. Nikolaev N. A., Martynov A. I., Drapkina O. M., Livzan M. A., Moiseev S. V. [et al.] The First Russian consensus on the quantitative assessment of the adherence to treatment. Therapy. 2018;5:11-32. https://doi.org/10.18565/therapy.2018.5.11-32
81. Nikolaev N. A., Skirdenko Y. P., Bunova S. S., Ershov A. V. Rational Pharmacotherapy in Cardiology: from Routine Control to Effective Management. Rational Pharmacotherapy in Cardiology. 2017;13(5):609-614. https://doi.org/10.20996/1819-6446-2017-13-5-609-614
82. Pogosova G. V. Compliance to treatment of arterial hypertension and ischemic heart disease – Key condition of lowering of cardiovascular mortality. Kardiologiia. 2007;3:79-84. [cited 05.01.2020]. Available at: https://www.researchgate.net/profile/Nana-Goar_Pogosova/publication/6335831_Compliance_to_treatment_of_arterial_hypertension_and_ischemic_heart_disease_-_Key_condition_of_lowering_of_cardiovascular_mortality/links/5770d3d008ae6219474882ca/Compliance-totreatment-of-arterial-hypertension-and-ischemic-heartdisease-Key-condition-of-lowering-of-cardiovascularmortality.pdf.
83. Jokisalo E., Enlund H., Halonen P., Takala J. Factors related to poor control of blood pressure with antihypertensive drug therapy. Blood Press. 2003;12(1):49-55. [cited 05.01.2020]. Available at: https://europepmc.org/article/med/12699136.
84. Strokova E. V., Naumova E. A., Schwartz Yu. G. Influence of an internal picture of illness, coping-strategies and the self-relation of the patients after myocardial infarction on adherence to long treatment of coronary artery disease and its regularity. Modern Studies of Social Issues. 2012;1:1169-1190. [cited 05.01.2020]. Available at: file:///C:/Users/Usere/Downloads/vliyanie-vnutrenneykartin-bolezni-koping-strategiy-i-samootnosheniyapatsientok-perenesshih-infarkt-miokarda-na-regulyarnosti-priverjennost-k-dlitelnoy-terapii-ishemicheskoy-bolezniserdtsa.pdf.
85. Strokova E. V., Naumova E. A., Shvarts Y. G. Dynamics of affective disorders during long-term atorvastatin taking, patients relation to illness and adherence to statin therapy of patients with high risk of manifestation of coronary artery disease. Sovremennye problemy nauki i obrazovaniya 2011;6:18. [cited 05.01.2020]. Available at: https://science-education.ru/pdf/2011/6/69.pdf.
86. Tarasenko E. V., Naumova E. A., Shvarc Yu. G. Priverzhennost’ k dlitel’nomu lecheniyu i faktory na nee vliyayushchie. Fundamental’nye issledovaniya. 2007;9:57-58. [cited 05.01.2020]. Available at: https://elibrary.ru/download/elibrary_12956141_66110970.pdf.
87. Conn V. S., Ruppar T. M., Chase J. A., Enriquez M., Cooper P. S. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr. Hypertens. Rep. 2015;17:94. [cited 05.01.2020]. Available at: https://link.springer.com/article/10.1007/s11906-015-0606-5.
88. Parati G., Omboni S. Role of home blood pressure telemonitoring in hypertension management: an update. Blood Press Monit. 2010;15:285–295. https://doi.org/10.1097/MBP.0b013e328340c5e4
89. Fletcher B. R., Hartmann-Boyce J., Hinton L., McManus R. J. The effect of selfmonitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am. J. Hypertens. 2015;28:1209-1221. https://doi.org/10.1093/ajh/hpv008
90. Konradi A. O., Polunicheva E. V. Nedostatochnaya priverzhennost’ k lecheniyu arterial’noj gipertenzii: prichiny i puti korrekcii. Arterial’naya gipertenziya. 2004;10(3):137-143.
91. Burnier M., Brede Y., Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int. J. Clin. Pract. 2011;65:127-133. https://doi.org/10.1111/j.1742-1241.2010.02616.x
92. Lowy A., Munk V. C., Ong S. H., Burnier M., Vrijens B. [et al.] Effects on blood pressure and cardiovascular risk of variations in patients’ adherence to prescribed antihypertensive drugs: role of duration of drug action. Int. J. Clin. Pract. 2011;65:41-53. https://doi.org/10.1111/j.1742-1241.2010.02569.x
93. Nikolaev N. A., Martynov A. I., Bojcov S. A., Drapkina O. M., Sychev D. A. [et al.] The first Russian consensus on quantitative assessment of treatment outcome. Medical News of North Caucasus. 2018;1.2(13):259-271. https://doi.org/10.14300/mnnc.2019.14072
94. Marcevich S. Yu., Kutishenko N. P., Tolpygina S. N., Lukina Yu. V. [et al.] Effektivnost’ i bezopasnost’ lekarstvennoj terapii pri pervichnoj i vtorichnoj profilaktike serdechnososudistyh zabolevanij. Rekomendacii VNOK, 2011. Rational Pharmacotherapy in Cardiology. 2011;7(5):2-72. https://doi.org/10.20996/1819-6446-2011-7-5
95. Martsevich S. Yu., Kutishenko N. P., Lukina Yu. V., Tolpygina S. N., Ivanova L. P. [et al.] Self-monitoring and treatment of chronic non-communicable diseases in the context of the COVID-19 pandemic. Consensus of experts of the National society of evidence-based pharmacotherapy and the Russian society of the prevention of non-communicable diseases. Cardiovascular Therapy and Prevention. 2020;19(3):2567. https://doi.org/10.15829/1728-8800-2020-2567
96. Skirdenko Y. P., Shustov A. V., Zherebilov V. V., Nikolayev N. A. Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms. Rational Pharmacotherapy in Cardiology. 2016;12(5):494-502. https://doi.org/10.20996/1819-6446-2016-12-5-494-502
97. Bunova S. S., Zhernakova N. I., Skirdenko Yu. P., Nikolaev N. A. Adherence to therapy, lifestyle modification and medical support of cardiovascular patients. Cardiovascular Therapy and Prevention. 2020;19(6):2665. https://doi.org/10.15829/1728-8800-2020-2665
98. Nikolaev N. A., Martynov A. I., Skirdenko Iu. P., Ageev F. T., Andreev K. A. [et al.] Management of treatment on the basis of adherence. Consensus document – Clinical recommendations. RSMSIM, SSGR, NATH, SEBN, GS RAS, RSH, RSP. Consilium Medicum. 2020;22(5):9-18. https://doi.org/10.26442/20751753.2020.5.200078
99. Skirdenko Y. P., Nikolaev N. A. Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2020;16(2):199-205. https://doi.org/10.20996/1819-6446-2020-04-16

Ключевые слова: приверженность, количественная оценка, лекарственная терапия, медицинское сопровождение, модификация образа жизни, управление лечением


Учредители:
Ставропольская государственная медицинская академия
Государственный научно-исследовательский институт курортологии
Пятигорская государственная фармацевтическая академия